Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board.

In his role at Blueprint Medicines, Dr. Namouni has demonstrated exceptional leadership in building the company's fully integrated business and advancing a broad pipeline of innovative medicines to address significant medical needs in oncology/hematology and allergy/inflammation. With over two decades of experience in clinical development, regulatory affairs, and medical affairs within the biotechnology and pharmaceutical industries, Dr. Namouni's insights and strategic guidance will be invaluable to Vor Bio as it continues to advance its novel approach to curing acute myeloid leukemia.

"We are thrilled to welcome Dr. Namouni to Vor Bio's Board of Directors," said Dr. Robert Ang, President and CEO of Vor Bio. "His deep oncology development experience will be invaluable as Vor Bio navigates toward late phase trials and beyond." Matthew R. Patterson, Chairman of Vor Bio, added, “Dr. Namouni’s decades of industry experience in both pharmaceutical and biotechnology research and development complements and strengthens the diverse perspectives on Vor’s Board and I look forward to working closely with him.”

Dr. Namouni has over 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. Prior to his current role as President of Research & Development, at Blueprint Medicines, Dr. Namouni held multiple senior leadership positions at Bristol-Myers Squibb where he played a pivotal role in the development and commercialization of groundbreaking oncology therapies including Opdivo and Yervoy. Throughout his career, Dr. Namouni has been dedicated to driving scientific innovation and improving patient outcomes.

“With innovative science, sound strategy and strong leadership, Vor Bio is poised to translate advances in cell and genome engineering into potential cures for acute myeloid leukemia and other blood cancers with high medical needs,” said Dr. Namouni. “I am pleased to join the Board and look forward to contributing my knowledge and experience in oncology and hematology drug development as the company continues to make progress in the clinic and work toward bringing important new medicines to patients.”